Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib

被引：0
|
作者：
Sharma, Ritul [1 ]
Frigault, Melanie M. [2 ]
Johnson, Amy J. [2 ]
Izumi, Raquel [2 ]
Hamdy, Ahmed [2 ]
Birkett, Joseph [2 ]
Stelte-Ludwig, Beatrix [3 ]
Maese, Luke [4 ]
Lacayo, Norman J. [5 ]
Narendran, Aru [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Vincerx Pharma, Palo Alto, CA USA
[3] Vincerx Pharma GmbH, Monheim, Germany
[4] Univ Utah, Primary Childrens Hosp, Salt Lake City, UT USA
[5] Stanford Univ, Dept Pediat, Bass Ctr Childhood Canc & Blood Disorders, Stanford, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180567
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 38 条
  • [21] Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation
    Chijimatsu, Ikue
    Imanaka, Yusuke
    Tomizawa, Daisuke
    Eguchi, Mariko
    Nishimura, Shiho
    Karakawa, Shuhei
    Miki, Mizuka
    Hamamoto, Kazuko
    Fujita, Naoto
    PEDIATRIC BLOOD & CANCER, 2017, 64 (12)
  • [22] CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial
    Froehling, Stefan
    Agrawal, Mridul
    Jahn, Nikolaus
    Fransecky, Lars R.
    Baldus, Claudia D.
    Waesch, Ralph
    Luebbert, Michael
    Walter, Gina
    Jensen, Patrizia
    Scholl, Claudia
    Habdank, Marianne
    Doehner, Konstanze
    Doehner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2016, 128 (22)
  • [23] Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia
    Cheung, Laurence C.
    Cruickshank, Mark N.
    Hughes, Anastasia M.
    Singh, Sajla
    Chua, Grace-Alyssa
    Ford, Jette
    Ferrari, Emanuela
    Oommen, Joyce
    Malinge, Sebastien
    Lock, Richard B.
    Kees, Ursula R.
    Kotecha, Rishi S.
    HAEMATOLOGICA, 2019, 104 (07) : e300 - e303
  • [24] Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
    Faulk, Kelly E.
    Kairalla, John A.
    Dreyer, ZoAnn E.
    Carroll, Andrew J.
    Heerema, Nyla A.
    Devidas, Meenakshi
    Carroll, William L.
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Hunger, Stephen P.
    Borowitz, Michael
    Wang, Cindy
    Guest, Erin
    Brown, Patrick A.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (09)
  • [25] High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling
    Wander, Priscilla
    Arentsen-Peters, Susan T. C. J. M.
    Vrenken, Kirsten S.
    Pinhancos, Sandra Mimoso
    Koopmans, Bianca
    Dolman, M. Emmy M.
    Jones, Luke
    Castro, Patricia Garrido
    Schneider, Pauline
    Kerstjens, Mark
    Molenaar, Jan J.
    Pieters, Rob
    Zwaan, Christian Michel
    Stam, Ronald W.
    BIOMEDICINES, 2022, 10 (03)
  • [26] Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial
    Fechina, Larisa
    Popov, Alexander
    Tsaur, Grigory
    Henze, Guenter
    Shorikov, Egor
    Makarova, Olga
    Khlebnikova, Olga
    Zhukova, Yulia
    Arakaev, Oleg
    Streneva, Olga
    Verzhbitskaya, Tatiana
    Riger, Tatiana
    Solodovnikov, Alexander
    Lapotentova, Elena
    Aleinikova, Olga
    Myakova, Natalia
    Boichenko, Elmira
    Kondratchik, Konstantin
    Nikonova, Olga
    Shapochnik, Alexander
    Goroshkova, Marina
    Ponomareva, Natalia
    Novichkova, Galina
    Karachunskiy, Alexander
    Roumiantsev, Alexander
    LEUKEMIA, 2023, 37 (11) : 2276 - 2281
  • [27] Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial
    Larisa Fechina
    Alexander Popov
    Grigory Tsaur
    Guenter Henze
    Egor Shorikov
    Olga Makarova
    Olga Khlebnikova
    Yulia Zhukova
    Oleg Arakaev
    Olga Streneva
    Tatiana Verzhbitskaya
    Tatiana Riger
    Alexander Solodovnikov
    Elena Lapotentova
    Olga Aleinikova
    Natalia Myakova
    Elmira Boichenko
    Konstantin Kondratchik
    Olga Nikonova
    Alexander Shapochnik
    Marina Goroshkova
    Natalia Ponomareva
    Galina Novichkova
    Alexander Karachunskiy
    Alexander Roumiantsev
    Leukemia, 2023, 37 : 2276 - 2281
  • [28] Minimal Residual Disease (MRD) Predicts Outcomes in KMT2A-Rearranged But Not KMT2A-Wild Type Infant Acute Lymphoblastic Leukemia (ALL): AALL0631, A Children's Oncology Group Study
    Brown, P.
    Kairalla, J.
    Hilden, J.
    Dreyer, Z.
    Carroll, A.
    Heerema, N. A.
    Devidas, M.
    Carroll, W.
    Raetz, E.
    Loh, M.
    Hunger, S.
    Borowitz, M.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S28 - S29
  • [29] Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A-Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers
    Lau, Jun
    Harman, Joe R.
    Jackson, Nicole E.
    Denny, Nicholas
    Smith, Alastair L.
    Vyas, Paresh
    Davies, James Oliver
    Hughes, Jim
    Crump, Nicholas
    Milne, Thomas Arthur
    BLOOD, 2023, 142
  • [30] FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631
    Patrick A. Brown
    John A. Kairalla
    Joanne M. Hilden
    ZoAnn E. Dreyer
    Andrew J. Carroll
    Nyla A. Heerema
    Cindy Wang
    Meenakshi Devidas
    Lia Gore
    Wanda L. Salzer
    Naomi J. Winick
    William L. Carroll
    Elizabeth A. Raetz
    Michael J. Borowitz
    Donald Small
    Mignon L. Loh
    Stephen P. Hunger
    Leukemia, 2021, 35 : 1279 - 1290
1234